Effect of Coenzyme Q10 on Left Ventricular Remodeling and Mortality in Patients With Heart Failure: A Meta-Analysis

Coenzyme Q10 in the treatment of heart failure: A systematic review of systematic reviews

“…Overall, among the meta-analyses that have examined the effect of CoQ10 supplementation on the NYHA classification, two cases had similar results and reported a significant change in NYHA classification, which correlated with an improvement (a decrease in severity) 33, 34…”

“…We included 2 Cochrane reviews25, 31 and 5 non-Cochrane systematic reviews32, 33 See Table 1 for a list of the reviews and the characteristics of the included reviews which have contributed to this review. A total of 7 systematic reviews were finally identified and most of them were good quality.…”

“…Additional larger studies are warranted and should examine whether there is an effect when this supplementation is added to the current standard of therapy for CHF or whether there is a dose-response effect between the stage of CHF at baseline and the dose of CoQ10 required for an improvement to be seen.EF = 3.67 (1.60, 5.74) (11 studies)NYHA = 0.30(0.66, 0.06) (3 studies) 25 Mohammed E Mamdani (2013)To review the safety and efficacy of Coenzyme Q10 in HF.914CoQ10YOf 7 trials which could be submitted to meta-analysis:The evidence collected shows no convincing evidence to support or refuse the use of Coenzyme Q10 for heart failure.Adequately powered and long-term conducted RCTs with low risk of bias are needed to support or change the current results Although Coenzyme Q10 is associated with improvement in the NYHA of clinical status and exercise capacity, the evidence is based on small trial numbers and is thus incomplete.Exercise duration = 12.79 [−140.12, 165.70] (2studies)Left ventricular EF = −2.26 [−15.49, 10.97] (2studies)serum levels of Coenzyme Q10 = 1.46 [1.19, 1.72] (3studies) 31 Nadine Flowers (2013)To determine the effects of coenzyme Q10 supplementation as a single ingredient for the primary prevention of CVD.218CoQ10YOf 7 trials which could be submitted to meta-analysis: Systolic blood pressure = Totals not selected (2sttudies)Our review produced few data with which to compare to previous studies and no conclusions can be drawn at present.Due to the small number of trials included, with a small number of participant's randomized, short follow-up and trials at some risk of bias, the results should be treated with caution. High-quality trials are needed to examine the effects of CoQ10 Supplementation on cardiovascular risk factors and events over a longer period of time.Diastolic blood pressure = −1.62 [-5.20, 1.96] (2studies)Total cholesterol = 0.30 [−0.10, 0.70] (1study)HDL-cholesterol = 0.02 [−0.13, 0.17] (1study)Triglycerides = 0.05 [−0.42, 0.52] (1study) 33 Angkawipa Trongtorsak (2016)To evaluate the effect of CoQ10 for left ventricular parameters and clinical outcomes in patients with HF1662…”

“…There is recent evidence for a role of CoQ10 as a predictor of outcomes and also as an adjunctive clinical therapy 37 . A recent systematic review reported that with CoQ10 supplement, plasma Q10 level was significantly higher (mean difference of 1.44 mcg/dL, 95% confidence interval (CI) 1.16–1.73 mcg/dL, p < 0.001) 33 . Another systematic review that combined data from two studies on the effect of CoQ10 on left ventricular ejection fraction showed that CoQ10 has no significant effect (MD −2.26;95% CI −15.49 to 10.97); in addition, the results showed that the use of CoQ10 increases its concentration in the blood (MD 1.46; 95% CI 1.19, 1.72) 38 .…”

“…During treatment, the EDVI was clearly improved in that the average patient in the CoQ10 group had a better score than 88% of the patients in the placebo group 32 . In a more recent meta-analysis, Trongtorsak et al reviewed 16 studies with a total of 1662 individuals, reporting that LVEF and LVESDg significantly improved by 2.9% with CoQ10 supplement, but not LVEDD 33 ,h. Cardiac output increased by an average of 0.28 L/min (0.03–0.53; P 0.96) for statistical heterogeneity.…”